by Gabrielle Morrow | Apr 16, 2020 | Press Release | 0 Comments
NEW YORK, April 16, 2020 (GlobeNewswire) — CERESPIR INCORPORATED, a pharmaceutical company engaged in the discovery and development of disease modifying therapeutics for the treatment of neurodegenerative diseases, announced today it has identified a possible... read more
by Gabrielle Morrow | Mar 26, 2019 | In the News, Press Release | 0 Comments
NEW YORK, March 26, 2019 (PR Newswire) — CERESPIR INCORPORATED, a pharmaceutical company engaged in the discovery and development of disease-modifying therapeutics for the treatment of neurodegenerative diseases, announced the formation of an expanded Clinical... read more
by Gabrielle Morrow | Dec 10, 2018 | Press Release | 0 Comments
Itanapraced blocks LRRK2 expression and LRRK2-mediated neurotoxicity Itanapraced ready to advance to Phase 2 in Parkinson’s disease patients with and without genetic mutation NEW YORK and SINGAPORE, Dec. 10, 2018 (GLOBE NEWSWIRE) — CERESPIR INCORPORATED a... read more
by Gabrielle Morrow | Jul 14, 2015 | Press Release | 0 Comments
NEW YORK, N.Y. – CereSpir™ Incorporated, a company with a novel approach to treat neurodegenerative diseases by harnessing the innate immune system, today announced the company has obtained a new patent from the United States Patent and Trademark Office (USPTO)... read more
by Gabrielle Morrow | Jul 1, 2015 | Press Release | 0 Comments
NEW YORK, N.Y. – CereSpir™ Incorporated, a company with a novel approach to treat neurodegenerative diseases by harnessing the innate immune system, today announced the company has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug... read more